Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CRMD CorMedix Inc
- Stocks
- Healthcare
- NYSEAMERICAN: CRMD
Price (delayed)
$12.53
Market cap
$849.84M
P/E Ratio
48.19
Dividend/share
N/A
EPS
$0.26
Enterprise value
$784.03M
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its
Highlights
CorMedix's net income has soared by 196% from the previous quarter and by 134% YoY
The EPS has surged by 187% since the previous quarter and by 128% year-on-year
The quick ratio fell by 38% YoY but it rose by 26% QoQ
Key stats
What are the main financial stats of CRMD
Market
Valuations
Earnings
Shares outstanding
67.82M
Market cap
$849.84M
Enterprise value
$784.03M
Price to earnings (P/E)
48.19
Price to book (P/B)
7.11
Price to sales (P/S)
9.9
EV/EBIT
45.54
EV/EBITDA
44.38
EV/Sales
9.5
Revenue
$82.55M
Gross profit
$78.59M
Operating income
$14.47M
Net income
$17.18M
EBIT
$17.22M
EBITDA
$17.67M
Free cash flow
-$13.63M
Per share
Balance sheet
Liquidity
EPS
$0.26
EPS diluted
$0.24
Free cash flow per share
-$0.21
Book value per share
$1.76
Revenue per share
$1.27
TBVPS
$2.27
Total assets
$149.58M
Total liabilities
$34.69M
Debt
$476,587
Equity
$114.89M
Working capital
$110.47M
Debt to equity
0
Current ratio
4.21
Quick ratio
3.84
Net debt/EBITDA
-3.73
Margins
Efficiency
Dividend
EBITDA margin
21.4%
Gross margin
95.2%
Net margin
20.8%
Operating margin
17.5%
Return on assets
17%
Return on equity
22.6%
Return on invested capital
53%
Return on capital employed
14.9%
Return on sales
20.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRMD stock price
How has the CorMedix stock price performed over time
Intraday
1.38%
1 week
-2.26%
1 month
37.69%
1 year
144.73%
YTD
54.69%
QTD
103.41%
Financial performance
How have CorMedix's revenue and profit performed over time
Revenue
$82.55M
Gross profit
$78.59M
Operating income
$14.47M
Net income
$17.18M
Gross margin
95.2%
Net margin
20.8%
CorMedix's net income has soared by 196% from the previous quarter and by 134% YoY
The company's operating income has surged by 165% QoQ and by 126% YoY
The company's net margin has surged by 150% QoQ
CorMedix's operating margin has surged by 134% QoQ
Price vs fundamentals
How does CRMD's price correlate with its fundamentals
Growth
What is CorMedix's growth rate over time
Valuation
What is CorMedix stock price valuation
P/E
48.19
P/B
7.11
P/S
9.9
EV/EBIT
45.54
EV/EBITDA
44.38
EV/Sales
9.5
The EPS has surged by 187% since the previous quarter and by 128% year-on-year
CorMedix's equity has surged by 98% YoY and by 36% QoQ
The P/B is 67% above the 5-year quarterly average of 4.2 and 27% above the last 4 quarters average of 5.5
The price to sales (P/S) is 99% lower than the 5-year quarterly average of 1642.6 and 89% lower than the last 4 quarters average of 91.0
The revenue has soared by 90% from the previous quarter
Efficiency
How efficient is CorMedix business performance
CorMedix's ROE has soared by 178% from the previous quarter and by 129% YoY
The ROA has soared by 176% from the previous quarter and by 125% YoY
The company's return on invested capital has surged by 172% QoQ and by 129% YoY
The return on sales has surged by 147% since the previous quarter
Dividends
What is CRMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRMD.
Financial health
How did CorMedix financials performed over time
CRMD's total assets has soared by 120% YoY and by 26% QoQ
The quick ratio fell by 38% YoY but it rose by 26% QoQ
The company's debt is 100% lower than its equity
CorMedix's debt to equity has shrunk by 100% QoQ and by 100% YoY
CorMedix's equity has surged by 98% YoY and by 36% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.